|1.||Vanasia, Massimo: 4 articles (01/2009 - 05/2002)|
|2.||Maggioni, Aldo Pietro: 3 articles (01/2009 - 05/2005)|
|3.||Masson, Serge: 3 articles (01/2009 - 05/2005)|
|4.||Mureddu, Gian Francesco: 3 articles (01/2009 - 05/2005)|
|5.||Latini, Roberto: 3 articles (01/2009 - 05/2005)|
|6.||de Simone, Giovanni: 3 articles (01/2009 - 05/2005)|
|7.||Boccanelli, Alessandro: 3 articles (01/2009 - 05/2005)|
|8.||Cacciatore, Giuseppe: 3 articles (01/2009 - 05/2005)|
|9.||Johnson, Myrtle J: 2 articles (05/2012 - 01/2010)|
|10.||Dasgupta, Amitava: 2 articles (05/2012 - 01/2010)|
06/01/2003 - "Canrenone attenuated LV dilation and interstitial remodeling, and improved LV filling dynamics and systolic function in the rat model of postinfarction heart failure. "
01/01/2009 - "Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results."
05/01/2002 - "Canrenone attenuates LV interstitial remodeling and reduces filling pressures in rats with postinfarction heart failure."
05/01/2002 - "Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure."
03/11/1977 - "Elimination of canrenone in congestive heart failure and chronic liver disease."
05/01/2002 - "Compared with placebo-infarcted rats, in the group treated with high canrenone dose there was a significant reduction of left ventricular systolic and end-diastolic pressures (-6.5% and -23%, respectively) and an attenuation of interstitial and perivascular fibrosis (-47% and -34%, respectively). "
06/01/2003 - "Canrenone attenuated LV remodeling, improved LV systolic and diastolic function, and markedly reduced interstitial and perivascular fibrosis. "
06/01/2003 - "Canrenone treatment was associated with a significant attenuation of LV dilation, better LV diastolic and systolic dynamics, and a marked reduction of reactive fibrosis. "
06/01/2002 - "In conclusion, canrenone normalizes the cardiac response to the postural challenge in patients with preascitic cirrhosis."
06/01/2002 - "Cardiovascular effects of canrenone in patients with preascitic cirrhosis."
11/01/2013 - "Canrenone seems to be effective in reducing some factors involved in metabolic syndrome and in improving insulin-resistance and the inflammatory state observed in these patients."
05/01/2014 - "Canrenone reduces the progression of insulin resistance and of microalbuminuria in type 2 diabetes and other related diseases. "
|4.||Hypertension (High Blood Pressure)
09/01/1988 - "These features have led to a hypothesis that competition between canrenone and endogenous digitalis-like materials, suggested to be involved in etiology of essential hypertension, could underly the antihypertensive effect of canrenone. "
12/08/1979 - "A double-blind study of Phanurane and placebo was conducted on 61 patients with mild essential hypertension. "
12/08/1979 - "[Effect and tolerance of Phanurane in the treatment of essential hypertension. "
01/01/2012 - "In this report, we describe a FH pediatric patient, remarkable both for age at onset and unusual presentation: a two-years old girl with polyuric-polydipsic syndrome and severe hypertension, successfully treated with canrenone and amiloride. "
11/01/2002 - "Therefore, we tested the hypothesis that the aldosterone antagonist canrenone can improve left ventricular diastolic function in essential hypertension. "
|5.||Systolic Heart Failure
|5.||Angiotensin Receptor Antagonists
|9.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|10.||Adrenocorticotropic Hormone (ACTH)